CD79A and nasopharyngeal carcinoma: Anti-EBV IgA antibody (e.g.,—early antigen [EA-IgA], anti–EBV capsid antigen [VCA-IgA], and anti–EBV nuclear antigen 1 [EBNA1-IgA]) serological testing is commonly used to detect asymptomatic nasopharyngeal carcinoma [92].